;
Skip to main content
Home > Week in Review > Clinical Status

Chronological Index of : Clinical Status

 Current Issue
  • AdipoCell: Clinical trial started

    Bioheart Inc. (OTCQB:BHRT), Sunrise, Fla. Product: AdipoCell, Adipose-derived stem cells (ADSC), LipiCell Business: Musculoskeletal Molecular target: NA Description: Adipose-derived stem cells designed to promote …

    Published on 4/14/2014
  • Clonidine: Phase III started

    Arcion Therapeutics Inc., Baltimore, Md. BioDelivery Sciences International Inc. (NASDAQ:BDSI), Raleigh, N.C. Product: Clonidine (clonidine topical gel) (formerly ARC-4558) Business: Neurology Molecular target: NA …

    Published on 4/14/2014
  • CyclASol: Phase I started

    Novaliq GmbH, Heidelberg, Germany Product: CyclASol Business: Ophthalmic Molecular target: NA Description: 0.05% clear cyclosporin solution developed using Novaliq's EyeSol semi fluorinated alkane (SFA) drug delivery …

    Published on 4/14/2014
  • DNA IL-12: Phase II ongoing

    OncoSec Medical Inc. (OTCBB:ONCS), San Diego, Calif. Product: DNA IL-12 (OMS ElectroImmunotherapy, ImmunoPulse) Business: Cancer Molecular target: Interleukin-12 (IL-12) Description: DNA plasmid coding for IL-12 …

    Published on 4/14/2014
  • Fruquintinib: Phase II started

    Hutchison China MediTech Ltd. (LSE:HCM), Hong Kong, China Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Product: Fruquintinib (HMPL-013) Business: Cancer Molecular target: NA Description: Small molecule that …

    Published on 4/14/2014
  • Glassia: Phase I/II started

    Kamada Ltd. (Tel Aviv:KMDA; NASDAQ:KMDA), Ness Ziona, Israel Product: Glassia (IV Alpha-1 Antitrypsin (AAT)) Business: Transplant Molecular target: Elastase Description: IV formulation of human plasma derived alpha 1-…

    Published on 4/14/2014
  • GRC 27864: Phase I start

    Glenmark Pharmaceuticals Ltd. (NSE:GLENMARK; BSE:532296), Mumbai, India Product: GRC 27864 Business: Autoimmune Molecular target: Microsomal prostaglandin E synthase-1 (PTGES) (mPGES-1) Description: Microsomal …

    Published on 4/14/2014
  • HaMPCs: Phase IIb

    Cellular Biomedicine Group Inc. (OTCQB:CBMG), Palo Alto, Calif. Product: HaMPCs, ReJoin Business: Autoimmune Molecular target: NA Description: Autologous human adipose tissue-derived mesenchymal precursor cells …

    Published on 4/14/2014
  • IC43: Phase II/III ongoing

    Valneva SE (Euronext:VLA; VSE:VLA), Lyon, France Product: IC43 Business: Infectious Molecular target: Not available Description: Recombinant subunit vaccine consisting of 2 outer membrane proteins of Pseudomonas …

    Published on 4/14/2014
  • IDX20963: Development discontinued

    Idenix Pharmaceuticals Inc. (NASDAQ:IDIX), Cambridge, Mass. Product: IDX20963 Business: Infectious Molecular target: Viral polymerase Description: Uridine nucleotide analog HCV NS5B polymerase inhibitor Indication: …

    Published on 4/14/2014
  • IDX21459: Phase I started

    Idenix Pharmaceuticals Inc. (NASDAQ:IDIX), Cambridge, Mass. Product: IDX21459 Business: Infectious Molecular target: NA Description: Uridine-based nucleotide prodrug Indication: Treat HCV infection Endpoint: Safety …

    Published on 4/14/2014
  • Ixmyelocel-T: Phase IIb ongoing

    Aastrom Biosciences Inc. (NASDAQ:ASTM), Ann Arbor, Mich. Product: Ixmyelocel-T (Expanded autologous mixed cell therapy) (formerly Vascular repair cells, Tissue repair cells, Cardiac Repair Cells (CRCs)) Business: …

    Published on 4/14/2014
  • Juxtapid: Phase III started

    Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR), Cambridge, Mass. Product: Juxtapid (Lojuxta - EU) lomitapide (AEGR-733) (formerly BMS-201038) Business: Endocrine/Metabolic Molecular target: Microsomal triglyceride transfer…

    Published on 4/14/2014
  • KD025: Phase IIa started

    Kadmon Corp. LLC, New York, N.Y. Nano Terra Inc., Brighton, Mass. Product: KD025 (formerly SLx-2119) Business: Autoimmune Molecular target: Rho-associated coiled-coil containing protein kinase 2 (ROCK2) Description: …

    Published on 4/14/2014
  • LY3009120: Phase I started

    Deciphera Pharmaceuticals LLC, Lawrence, Kan. Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Product: LY3009120, DP-4978 Business: Cancer Molecular target: BRAF; CRAF (RAF1) Description: Oral small molecule pan-…

    Published on 4/14/2014
  • Myrcludex B: Pilot trial started

    Hepatera LLC, Moscow, Russia MYR GmbH, Burgwedel, Germany Product: Myrcludex B Business: Infectious Molecular target: NA Description: Fragment of the pre-S1 surface peptide that targets a receptor of mature hepatocytes …

    Published on 4/14/2014
  • Nano-Cancer: Postmarketing study started

    MagForce AG (Xetra:MF6), Berlin, Germany Product: Nano-Cancer (NanoTherm Therapy) Business: Cancer Molecular target: Not applicable Description: Injectable iron oxide-coated nanoparticles heated by an external magnetic …

    Published on 4/14/2014
  • Onapristone ER: Phase I/II started

    Arno Therapeutics Inc. (OTCQB:ARNI), Flemington, N.J. Invivis Pharmaceuticals Inc., Bridgewater, N.J. Product: Onapristone ER Business: Cancer Molecular target: Progestin receptor Description: Extended-release …

    Published on 4/14/2014
  • PEGPH20: Phase II hold

    Halozyme Therapeutics Inc. (NASDAQ:HALO), San Diego, Calif. Product: PEGPH20 (formerly PEGrHuPH20) Business: Cancer Molecular target: Hyaluronan Description: Recombinant human PH20 hyaluronidase enzyme conjugated to …

    Published on 4/14/2014
  • Prurisol abacavir acetate: Phase I started

    Cellceutix Corp. (OTCQB:CTIX), Beverly, Mass. Product: Prurisol abacavir acetate (KM-133) Business: Autoimmune Molecular target: NA Description: Small molecule ester of abacavir, a synthetic nucleoside analogue …

    Published on 4/14/2014
  • PRX002: Phase I started

    Prothena Corp. plc (NASDAQ:PRTA), Dublin, Ireland Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Product: PRX002 Business: Neurology Molecular target: Alpha synuclein (SNCA) Description: mAb targeting alpha synuclein…

    Published on 4/14/2014
  • Quizartinib: Phase I/II ongoing

    Ambit Biosciences Corp. (NASDAQ:AMBI), San Diego, Calif. Product: Quizartinib (AC220) Business: Cancer Molecular target: FMS-like tyrosine kinase 3 (FLT3) (CD135) Description: Oral small molecule FMS-like tyrosine …

    Published on 4/14/2014
  • Quizartinib: Phase III started

    Ambit Biosciences Corp. (NASDAQ:AMBI), San Diego, Calif. Product: Quizartinib (AC220) Business: Cancer Molecular target: FMS-like tyrosine kinase 3 (FLT3) (CD135) Description: Oral small molecule FMS-like tyrosine …

    Published on 4/14/2014
  • Recombinant human nerve growth factor: Phase Ib/II started

    Dompe Farmaceutici S.p.A., Milan, Italy Product: Recombinant human nerve growth factor (rhNGF) Business: Ophthalmic Molecular target: NA Description: Recombinant human nerve growth factor (rhNGF) Indication: Treat …

    Published on 4/14/2014
  • ReN001: Phase I start

    ReNeuron Group plc (LSE:RENE), Guildford, U.K. Product: ReN001 Business: Cardiovascular Molecular target: Not applicable Description: Cell therapy consisting of neural stem cells derived from ReNeuron's c-mycER …

    Published on 4/14/2014

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993